All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can we improve on current risk stratification in MDS?

Jan 18, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, How can we improve on current risk stratification in MDS?

How can we improve on current risk stratification in MDS?

In daily practice, the International Prognostic Scoring System (IPSS) and the revised IPSS are used for assessing prognosis and stratification of patients with MDS at diagnosis. However, in recent years, a lot of data have shown the impact of mutations in patients with MDS. Most of these mutations confer a poor prognosis when added to these risk stratification systems. Platzbecker underlines the importance of integrating these mutations into a holistic prognostication system, which should also include fatigue and patient-reported outcomes. 

 

Share: